Tagrisso is a cancer medicine used to treat non-small cell lung cancer.
This medicine contains osimertinib, a substance that blocks the function of EGFR, a cancer cell receptor that controls its growth and multiplication, so tumor cells cannot develop properly and the rate of cancer development slows down, improving the outcome of other treatments. like chemotherapy.
- Tagrisso is produced by AstraZeneca Laboratories and can be purchased from a prescription pharmacy.
- In the form of 40 or 80 mg tablets.
Although this drug has already been approved by Anvisa in Brazil, it is not yet marketed.
Tagrisso is indicated for the treatment of adults with locally advanced non-small cell lung cancer or metastasis with a positive T790M mutation in the EGFR receptor gene.
Treatment with this medicine should always be guided by the oncologist, depending on the degree of development of the cancer.
However, the recommended dose is 1 80 mg tablet or 2 40 mg tablets once daily.
The use of Tagrisso can cause certain side effects such as diarrhea, stomach pain, hives and itchy skin and changes in blood tests, especially the number of platelets, leukocytes and neutrophils.
Tagrisso should not be used by pregnant or nursing women, as well as by people allergic to any of the ingredients of the formula. In addition, you should not take St. John’s wort during treatment with this medicine.